Tag:
comeback
Latest Headlines
Latest Headlines
Tysabri: The comeback kid
Call Tysabri the comeback kid. The multiple sclerosis drug, made by Elan and Biogen Idec, was pulled from the U.S. market in 2005 after reports of its links to a
THE LIBRARY: WEBINAR
Getting the most PoC data in Phase I cancer studies
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
EVENTS
- MDMA Annual Meeting May 30th - June 1st, 2012 — Washington, DC
- Clinical Trials Eastern Europe Webinar SeriesMay 15-June 12 — Eastern Europe
- What's your BIO?June 18-21, 2012 — Boston, MA
Press Releases
- Chronic Pain Is Relieved by Cell Transplantation in Lab Study
- Drug-vaccine combo better for breast cancer
- Marked for destruction: Newly developed compound triggers cancer cell death
- Orthofix International Completes Divestiture of Sports Medicine Business Unit
- ConforMIS iTotal CR Knee Replacement System Wins Silver in 2012 Medical Design Excellence Awards
- More Press Releases
Featured Jobs
-
Regulatory Scientist Assistant III (Senior) Job
Yoh - Kenilworth, NJ, USA -
Sr. Director, Healthcare Compliance Audit Job
Celgene Corporation - Summit, NJ, US -
Statistician Job
Yoh - Montville, NJ, USA -
Associate Director, Manufacturing Operations Job
Celgene Corporation - Basking Ridge, NJ, US -
Senior Manager, Clinical Data Management
TESARO - Waltham, MA
